The Medical Letter on Drugs and Therapeutics
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
More Resistance to Oseltamivir (Tamiflu)

Since publication of our recent article on antiviral drugs for influenza,1 increased levels of resistance to oseltamivir (Tamiflu) have been detected in influenza A H1N1 strains.

CIRCULATING STRAINS — About 80% of the influenza strains circulating this season are influenza A. The 2 strains of influenza A are H1N1 and H3N2. Almost 99% of the H1N1 isolates that have been tested are resistant to oseltamivir (compared to 11% last year); none are resistant to zanamivir (Relenza) or to the adamantanes rimantadine (Flumadine, and others) and amantadine (Symmetrel, and others).2 H3N2 and influenza B remain susceptible to oseltamivir as well as zanamivir; both are resistant to amantadine and rimantadine.

DIAGNOSTIC TESTING — Rapid tests of nasopharyngeal swabs and washings can diagnose influenza, and some can ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1304
 Downloadable, electronic issue - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian